Symphogen is leading the development of antibody mixture therapeutics to improve the treatment of cancer.
Symphogen's growing pipeline of cancer programs reflects a new approach to fighting cancer with unique mechanisms based on multiple simultaneous attacks on tumors. The result is improved efficacy and the potential to reduce the development of drug resistance.
EUhelp NETVÆRKS- OG INSPIRATIONSMØDE
Kirsten Drejer, CEO
Strategic Protein Formulation and Drug Delivery conference
Marina R. Kosimova, Senior Scientist
AACR Annual Meeting 2014
- More events